Australia's most trusted
source of pharma news
Posted 25 November 2025 PM
MSAC has dealt blow to Eli Lilly in its bid to provide its Alzheimer's drug Kisunla to the Australian population, failing to support Government funding for necessary tests which have an estimated price tag of a billion dollars over six years.
In the latest challenge to funded access to the new treatment, MSAC said it did not support public funding on the MBS for two tests that can determine eligibility for treatment with Kisunla by checking for amyloid-beta proteins in the brain.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.